RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday

investorplace2021-04-27

Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（6）

S土豪熊貓G
·2021-04-27
Finally soring. Easily hit $10. Buy buy buy
Reply
Like
Report
Stevenoh
·2021-04-27
Latest??
Reply
1
Report
Fold Replies
- ekhao:
  nice
  2021-04-27
  Reply
  Report
idkwhatimdoi
·2021-04-27
??
Reply
3
Report
Fold Replies
- lzh77:
  ?
  2021-04-27
  Reply
  Report
LeeWan
·2021-04-27
Why
Reply
1
Report
Fold Replies
- idkwhatimdoi:
  agree
  2021-04-27
  Reply
  Report
- Zhenghao:
  Nice
  2021-04-27
  Reply
  Report
Suresh999
·2021-04-27
Can consider
Reply
1
Report
KLooi
·2021-04-27
nice
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1183769970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-27 13:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183769970","market":"us","top_or_hot":-1,"title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","media":"investorplace","content":"<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVPH","symbol_name":"Reviva Pharmaceuticals Holdings, Inc.","start_time":0,"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","article_id":"1183769970","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","pubTimestamp":1619501541,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"translate_title":"RVPH股票：为什么瑞沃制药周一暴涨90%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVPH":0.9},"content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":377693550,"gmtCreate":1619521001070,"gmtModify":1704725311264,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Finally soring. Easily hit $10. Buy buy buy&nbsp;","listText":"Finally soring. Easily hit $10. Buy buy buy&nbsp;","text":"Finally soring. Easily hit $10. Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377693550","repostId":1183769970,"repostType":2,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":377192191,"gmtCreate":1619502709213,"gmtModify":1704725034024,"author":{"id":"3580551463324218","authorId":"3580551463324218","name":"Stevenoh","avatar":"https://static.tigerbbs.com/2864e71b7de77c92cd605a0a430bc5f1","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3580551463324218","authorIdStr":"3580551463324218"},"htmlText":"Latest??&nbsp;","listText":"Latest??&nbsp;","text":"Latest??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377192191","repostId":1183769970,"repostType":4,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4147472,"gmtCreate":1619503609918,"gmtModify":1680785806164,"authorId":3574324990111810,"author":{"id":3574324990111810,"idStr":"3574324990111810","authorId":3574324990111810,"name":"ekhao","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":377192191,"type":1,"supId":0,"prevId":0,"content":"nice","text":"nice","html":"nice"}],"langContent":"EN"},{"id":377191868,"gmtCreate":1619502527554,"gmtModify":1704725028988,"author":{"id":"3582094048004898","authorId":"3582094048004898","name":"idkwhatimdoi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582094048004898","authorIdStr":"3582094048004898"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/377191868","repostId":1183769970,"repostType":4,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4147328,"gmtCreate":1619502711160,"gmtModify":1680785807683,"authorId":3581654499912172,"author":{"id":3581654499912172,"idStr":"3581654499912172","authorId":3581654499912172,"name":"lzh77","avatar":"https://static.tigerbbs.com/37282f661827d98da9d277ecf852cb00","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.12","exceedPercentage":"60.15%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":377191868,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":377104625,"gmtCreate":1619502160167,"gmtModify":1704725022189,"author":{"id":"3558097748623340","authorId":"3558097748623340","name":"LeeWan","avatar":"https://static.tigerbbs.com/88769849d29a340fce73355c249755a4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3558097748623340","authorIdStr":"3558097748623340"},"htmlText":"Why","listText":"Why","text":"Why","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/377104625","repostId":1183769970,"repostType":4,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4147329,"gmtCreate":1619502728470,"gmtModify":1680785811053,"authorId":3582094048004898,"author":{"id":3582094048004898,"idStr":"3582094048004898","authorId":3582094048004898,"name":"idkwhatimdoi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":377104625,"type":1,"supId":0,"prevId":0,"content":"agree","text":"agree","html":"agree"},{"id":4147306,"gmtCreate":1619502469334,"gmtModify":1680785806941,"authorId":3577189579318003,"author":{"id":3577189579318003,"idStr":"3577189579318003","authorId":3577189579318003,"name":"Zhenghao","avatar":"https://static.tigerbbs.com/9bc02f1c85fb8e61dbc393ac0ad551db","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":377104625,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":377102211,"gmtCreate":1619501967233,"gmtModify":1704725018951,"author":{"id":"3581644896223732","authorId":"3581644896223732","name":"Suresh999","avatar":"https://static.tigerbbs.com/b75e0b2611994b10d3585f3fd574711f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581644896223732","authorIdStr":"3581644896223732"},"htmlText":"Can consider&nbsp;","listText":"Can consider&nbsp;","text":"Can consider","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377102211","repostId":1183769970,"repostType":4,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":377109590,"gmtCreate":1619501608110,"gmtModify":1704725011940,"author":{"id":"3581976397075140","authorId":"3581976397075140","name":"KLooi","avatar":"https://static.tigerbbs.com/5cf24a7f715799a8baa65a736d1f1318","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581976397075140","authorIdStr":"3581976397075140"},"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/377109590","repostId":1183769970,"repostType":4,"repost":{"id":"1183769970","kind":"news","pubTimestamp":1619501541,"share":"https://ttm.financial/m/news/1183769970?lang=&edition=fundamental","pubTime":"2021-04-27 13:32","market":"us","language":"en","title":"RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1183769970","media":"investorplace","summary":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of","content":"<p>Today, investors in&nbsp;<b>Reviva Pharmaceuticals</b>(NASDAQ:<b><u>RVPH</u></b>) and&nbsp;RVPH stock are seeing explosive gains of more than 90% at the time of writing.</p><p>Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.</p><p>Let’s dive more into the announcement that has Reviva shares soaring today.</p><p><b>RVPH Stock Moving on Positive Clinical Trial Results</b></p><p>Today, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:</p><ul><li>The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”</li><li>According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”</li><li>The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”</li><li>Reviva says it also “improved social functioning and cognition.”</li><li>Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”</li></ul><p>Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.</p><p>The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”</p><p><b>The Bottom Line</b></p><p>These details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-27 13:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage ...</p>\n\n<a href=\"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RVPH":"Reviva Pharmaceuticals Holdings, Inc."},"source_url":"https://investorplace.com/2021/04/rvph-stock-why-reviva-pharmaceuticals-is-skyrocketing-90-on-monday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1183769970","content_text":"Today, investors in Reviva Pharmaceuticals(NASDAQ:RVPH) and RVPH stock are seeing explosive gains of more than 90% at the time of writing.Today’s move nearly doubles the clinical-stage biopharmaceutical company’s market capitalization to more than $70 million. As a small-cap biopharma play, such moves aren’t terribly out of the ordinary, especially when companies like Reviva report significantnews.Let’s dive more into the announcement that has Reviva shares soaring today.RVPH Stock Moving on Positive Clinical Trial ResultsToday, Revivaannounceddetails of its Phase 2 clinical trial for the company’s acute schizophrenia drug. These results were overly positive, with the following key points noted by Reviva’s management team:The candidate “met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder.”According to Reviva, it also “met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia.”The candidate, RP5063, also “mitigated positive symptoms and negative symptoms.”Reviva says it also “improved social functioning and cognition.”Lastly, the study found “no metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.”Indeed, the company’s RP5063 (Brilaroxazine) drug for acute schizophrenia is one investors in RVPH stock have been keeping a close eye on. These results appear to show efficacy, and investors are pricing in higher expectations of FDA approval in RVPH stock today.The company noted that positive and negative symptoms were mitigated by its Brilaroxazine drug. Additionally, patients achieved improved social functioning and cognition. According to the company, “the FDA has agreed to consider a potential ‘Superior Safety’ label claim, if there is a positive outcome on a relevant endpoint in a pivotal Phase 3 clinical study in schizophrenia.”The Bottom LineThese details certainly give Reviva investors a lot to be excited about today. That said, investors looking at such clinical-stage biopharma companies may want to hold a diversified portfolio. Proper portfolio discipline is always encouraged, but in cases of higher-risk speculative names, additional care should be taken with position sizing and portfolio design.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":22,"commentSize":6,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}